Clinical Trial Update: Sequential Regimen of Bendamustine-Debulking Followed by ABT-199 and GA101-Induction and -Maintenance in CLL (CLL2-BAG) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a sequential regimen of bendamustine debulking followed by venetoclax (ABT-199) and obinutuzumab (GA101) induction and maintenance in c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• ABT-199 (venetoclax) (venetoclax)
• Bendamustine (Bendamustine)
• GA101 (obinutuzumab) (obinutuzumab)

Snippet

Sponsor: German CLL Study Group | Conditions: Chronic Lymphocytic Leucemia | Phase 2 | Status: COMPLETED